|
A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children Clinical research trials and A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children. A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children clinical trial. Test subjects typically obtain the finest healthcare available for their A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children  A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children
A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children
For Condition: HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) , Boehringer Ingelheim Pharmaceuticals
Synopsis: To generate initial information on the pharmacokinetics (blood levels) and dose proportionality of nevirapine (BI-RG-587) plasma levels in HIV-infected children; to assess the safety and tolerance of single rising oral doses of nevirapine in HIV-infected children; and to confirm that the single doses that achieve certain plasma levels in adults achieve similar levels in HIV-infected children. Test tube studies have shown that nevirapine (BI-RG-587) inhibits replication (reproduction) of HIV. Nevirapine works with zidovudine (AZT) and is active against strains of the virus that are resistant to AZT. Studies of the drug in HIV-infected adults showed no serious adverse effects.
Details: Test tube studies have shown that nevirapine (BI-RG-587) inhibits replication (reproduction) of HIV. Nevirapine works with zidovudine (AZT) and is active against strains of the virus that are resistant to AZT. Studies of the drug in HIV-infected adults showed no serious adverse effects. Two doses, given by mouth, are evaluated: Three patients receive the lower dose, and 7 days after the third patient receives the lower dose, three additional patients receive the higher dose. After dosing, blood is drawn at 1, 2, 4, 8, 24, 48, 96, 168 hours to measure blood levels of the drug.
Eligibility:
Study Type: Interventional, Treatment, Dose Comparison, Safety Study
Minimum Age/Maximum Age: 2 Months/13 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Intravenous gammaglobulin. Pneumocystis prophylaxis according to published guidelines. Patients must have the following: - HIV infection. - Parent or guardian must be available to give written informed consent. Exclusion Criteria Concurrent Medication: Excluded: - Zidovudine (AZT). - Steroid dependency. Excluded within 1 hour before and 4 hours after study drug administration: - Drugs that might interfere with the absorption of study drug (H2 blockers, antacids, carafate, cholestyramine). - Benzodiazepines. - Alcohol-containing substances. Concurrent Treatment: Excluded: - Requiring supplemental oxygen. Patients with the following are excluded: - Active opportunistic or serious bacterial infection. - Lymphoid interstitial pneumonitis (LIP) and steroid dependent or requiring supplemental oxygen or have a pretreatment pa02 < 70 mm Hg. - Pre-existing malignancies. Prior Medication: Excluded: - Zidovudine (AZT) within 7 days prior to administration of study drug. Excluded for at least 4 weeks prior to drug administration: - Other approved or investigational antiretroviral agents. All other investigational agents. Biologic response modifiers (e.g., interferon) or immunomodulators. Immunosuppressive agents (including glucocorticoids). Coumadin and other anticoagulant medications. Prior Treatment: Excluded: - Red blood cell transfusion within 4 weeks of study entry. Patients may not have the following: - Opportunistic or serious bacterial infection. Zidovudine (AZT) > 7 days prior to administration of study drug. Active alcohol or drug abuse.
Total Enrollment: 6
Location and Contact Information:
Univ of Massachusetts Med Ctr / Biotech II
Worcester, Massachusetts, 01605
United States
Additional Information:
Study ID Numbers: ACTG 165; 00853
Study Start Date:
Record last reviewed: April 1996
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000634
Other Hiv Infections Studies:
1. Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment
2. A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies with Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient
3. Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination with AIDSVAX B/B
4. A Study of DAPD Alone Versus DAPD Plus MMF for Treatment of HIV Infection
5. The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs
Related Studies:
Other HIV Infections Clinical Trials
Other Massachusetts Clinical Trials
Other Worcester Clinical Trials
A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children
|
|
|
|
|
|
|
|
